This phase I/II dose escalation and expansion study is trying to understand how safe and effective a new drug (TAK-280) is in people with locally advanced or metastatic cancer that is unable to be removed with surgery.
This trial is treating patients with unresectable, locally advanced or metastatic cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has not spread to other parts of the body.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
This study consists of 2 phases: dose escalation and cohort expansion. The objective of the Dose Escalation Phase is to determine the recommended dose of TAK-280 for the cohort expansion phase. The Cohort Expansion Phase will consist of 5 separate participant cohorts, based on their cancer type. TAK-280 will be administered via intravenous infusion (IV) for up to 14 treatment cycles.
Recruiting Hospitals Read More